Regular Article

British Journal of Cancer (2001) 84, 626–630. doi:10.1054/bjoc.2000.1650 www.bjcancer.com
Published online 27 February 2001

Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia

D R Collingridge1, S A Hill2 and D J Chaplin3

  1. 1PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, MRC Cyclotron Building, Du Cane Road, London, W12 0NN, UK
  2. 2Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK
  3. 3Oxigene Inc, 321 Arsenal Street, Watertown, Boston, MA 02472, USA

Received 26 July 2000; Revised 20 November 2000; Accepted 30 November 2000.

Top

Abstract

Macrophages can account for up to 50% of tumour mass and secrete many angiogenic factors. Furthermore, tumour hypoxia is thought to play a major role in the activation of macrophages and the regulation of angiogenesis. In this paper, we demonstrate a strong correlation between hypoxia and the recruitment of immune cells binding to IgG in 8 experimental tumours. We provide evidence that IgG binding immune cells in 3 tumour lines are predominately composed of macrophages. Reduced oxygenation may act as a stimulus for recruitment of immune cells to the tumour mass, and the detection of either IgG-positive host cells or macrophages may offer an alternative method for monitoring tumour hypoxia. © 2001 Cancer Research Campaign

Keywords:

hypoxia, macrophage, angiogenesis, pO2histograph, flow cytometry

Top

References

  1. Aboagye EO, Kelson AB, Tracy M and Workman P (1998) Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumour hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticanc Drug Des 13: 703–730
  2. Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T and Duncan JS (1999) [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurol 53: 2199–2203
  3. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR and Dewhirst DW (1996) Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941–943 | PubMed | ISI | ChemPort |
  4. Chaplin DJ, Durand RE and Olive PL (1985) Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer 51: 569–572 | PubMed | ISI | ChemPort |
  5. Collingridge DR, Young WK, Vojnovic B, Wardman P, Lynch EM, Hill SA and Chaplin DJ (1997) Measurement of tumour oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res 147: 329–334 | Article | PubMed | ISI | ChemPort |
  6. Collingridge DR, Piepmeier JM, Rockwell S and Knisely JPS (1999) Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53: 127–131 | Article | PubMed | ISI | ChemPort |
  7. Dachs GU and Stratford IJ (1996) The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 74: S126–S132 | ISI |
  8. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR Jr and Koch CJ (2000) Non-invasive detection of tumour hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41: 327–336
  9. Gray LH, Conger AD, Ebert M, Hornsey S and Scott OCA (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638–648 | PubMed | ISI | ChemPort |
  10. Harmey JH, Dimitriadis E, Kay E, Redmond HP and Bouchier-Hayes D (1998) Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. An Surg Oncol 5: 271–278
  11. Höckel M, Knoop C, Schlenger K, Vorndran B, Baus zligmann E, Mitze M, Knapstein P-G and Vaupel P (1993) Intertumoural pO2predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45–50 | Article | PubMed | ISI | ChemPort |
  12. Hoskin PJ, Saunders MI, Phillips H, Cladd H, Powell MEB, Goodchild K, Stratford MR and Rojas A (1997) Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 76: 260–263 | PubMed | ISI | ChemPort |
  13. Hume DA and Gordon S (1983) Mononuclear phagocyte system of the mouse defined by immunochemical localisation of antigen F4/80: identification of resident macrophages in medullary and cortical interstitium and the juxtaglomerular complex. J Exp Med 157: 1704–1709 | Article | PubMed | ChemPort |
  14. Kelly PM, Davison PS, Bliss E and McGee JO'D (1988) Macrophages in human breast tumours: a quantitative immunohistochemical study. Br J Cancer 57: 174–177 | PubMed | ISI | ChemPort |
  15. Leek RD, Harris AL and Lewis CE (1994) Cytokine networks in solid tumours: regulation of angiogenesis. J Leukoc Biol 55: 410–422 | PubMed | ISI | ChemPort |
  16. Leek RD, Lewis CE and Harris AL (1997) The role of macrophages in tumour angiogenesis. In: Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds). Oxford University Press
  17. Leek RD, Landers RJ, Harris AL and Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991–995 | Article | PubMed | ISI | ChemPort |
  18. Lewis JS, Lee JA, Underwood JCE, Harris AL and Lewis CE (1999) Macrophage responses to hypoxia: relevance to disease mechanisms. J Leuko Biol 66: 889–900
  19. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Li J, Sellke F, Carmeliet P and Simons M (2000) PR39, a peptide regulator of angiogenesis. Nat Med 6: 49–55 | Article | PubMed | ISI | ChemPort |
  20. Mantovani A, Bottazzi B, Collatta F, Sozzani S and Ruco L (1992) The origin and function of tumour-associated macrophages. Immunol Today 13: 265–270 | Article | PubMed | ISI | ChemPort |
  21. Milas L, Kogelnik HD, Basic I, Mason K, Hunter N and Withers HR (1975) Combination of C. parvum and specific immunization against artificial pulmonary metastases in mice. Int J Cancer 16: 738–746
  22. Milas L, Faykus MH Jr, McBride WH, Hunter N and Peters LJ (1984) Concomitant development of granulocytosis and enhancement of metastases formation in tumour-bearing mice. Clin Exp Met 2: 181–190
  23. Milas L, Wike J, Hunter N, Volpe J and Basic I (1987) Macrophage content of murine sarcomas and carcinomas: associations with tumour growth and tumour radiocurability. Cancer Res 47: 1069–1075 | PubMed | ISI | ChemPort |
  24. Nordsmark M, Overgaard M and Overgaard J (1997) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31–39
  25. O'Hara JA, Goda F, Demidenko E and Swartz HM (1998) Effect on regrowth delay in a murine tumour of scheduling split-dose irradiation based on direct pO2measurements by electron paramagnetic resonance oximetry. Radiat Res 150: 549–556
  26. O'SullivanLewis CE (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172: 229–235 | Article | PubMed | ChemPort |
  27. Olive PL (1989) Distribution, oxygenation, and clonogenicity of macrophages in a murine tumour. Cancer Commun 1: 93–100
  28. Ozaki H, Yu AY, Della N, Ozaki K, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL and Campochiaro PA (1999) Hypoxia inducible factor-1alpha is increased in ischaemic retina: temporal and spatial correlation with VEGF expression. Invest Opthal Vis Sci 40: 182–189
  29. Saunders MI and Dische S (1996) Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 74: S271–S278 | ISI | ChemPort |
  30. Svennevig J-L, Lovik M and Woerner D (1979) Isolation and characterisation of lymphocytes and macrophages from solid, malignant human tumours. Int J Cancer 23: 626–631
  31. Teicher BA, Lazo JS and Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumour cells. Cancer Res 41: 73–81 | PubMed | ISI | ChemPort |
  32. Tocher JH (1997) Reductive activation of nitroheterocyclic compounds. Gen Pharmac 28: 485–487
  33. Twentyman PR, Brown MJ, Gray JW, Franko AJ, Scoles MA and Kallman RF (1980) A new mouse tumour model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64: 595–604 | PubMed | ChemPort |
  34. Voogd CE (1981) On the mutagenicity of nitroimidazoles. Mutat Res 86: 243–277
  35. Zavala F and Lenfant M (1987) Benzodiazepines and PK11195 exert immunomodulating activities by binding on a specific receptor on macrophages. An New York Acad Sci 496: 240–249